Cardiovascular Systems, Inc. (CSI) CSII, will present late-breaking
data from its CONFIRM study series, an oral abstract from its CALCIUM study,
and conduct other educational and poster sessions at the 25^th annual
International Symposium on Endovascular Therapy (ISET) conference in Miami,
Jan. 19–23, 2013.
The CONFIRM study series evaluated the safety and procedural effectiveness of
CSI's orbital atherectomy system as a treatment for peripheral arterial
disease (PAD) —above- and below-the-knee lesions— in a real world population
of patients (no exclusions). Eighty-one percent of the lesions had severe or
moderate calcification—historically considered a difficult patient population
to treat. CONFIRM, like other studies in CSI's growing body of clinical
research, is aimed at providing physicians with scientific data to make sound
treatment decisions.
Arterial calcification is a common, underdiagnosed condition with complicating
factors—including a higher frequency of dissections and perforations—that pose
a challenge for physicians treating PAD. Calcified lesions are estimated to be
present in approximately 65 percent of the people treated annually for PAD and
are more prevalent in distal vessels below the knee.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in